Acinetobacter Infections Treatment Market – Global Outlook and Forecast 2022-2028

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or ?species? of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
This report contains market size and forecasts of Acinetobacter Infections Treatment in Global, including the following market information:
Global Acinetobacter Infections Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Acinetobacter Infections Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Sulbactam Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Acinetobacter Infections Treatment include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics and Achaogen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Acinetobacter Infections Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acinetobacter Infections Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Acinetobacter Infections Treatment Market Segment Percentages, by Type, 2021 (%)
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Global Acinetobacter Infections Treatment Market, by Pipeline, 2017-2022, 2023-2028 ($ millions)
Global Acinetobacter Infections Treatment Market Segment Percentages, by Pipeline, 2021 (%)
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
Global Acinetobacter Infections Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Acinetobacter Infections Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acinetobacter Infections Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Acinetobacter Infections Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals